SAFETY DATA SHEET

Date of issue/Date of revision

: 7 November 2022



: 1

Version

SECTION 1: Identification of the substance/mixture and of the company/ undertaking

1.1 Product identifier	
Product name	: SIGMALINE 859 REP HARDENER
Product code	: 00168694
Product description	1 · · · · · · · · · · · · · · · · · · ·
Product type	: Liquid.
Other means of identification	: Not available.
1.2 Relevant identified uses of	of the substance or mixture and uses advised against
Product use	: Professional applications, Used by spraying.
Use of the substance/ mixture	: Coating.
Uses advised against	: Product is not intended, labelled or packaged for consumer use.

1.3 Details of the supplier of the safety data sheet

PPG Coatings Belgium BV/SRL Tweemontstraat 104 B-2100 Deurne Belgium Telephone +32-33606311 Fax +32-33606435

e-mail address of person : Product.Stewardship.EMEA@ppg.com responsible for this SDS

1.4 Emergency telephone number

- **Supplier**
 - +31 20 4075210

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Product definition : Mixture Classification according to UK CLP/GHS

Flam. Liq. 3, H226 Acute Tox. 4, H332 Skin Irrit. 2, H315 Eye Irrit. 2, H319 Resp. Sens. 1, H334 Skin Sens. 1, H317 Carc. 2, H351 STOT SE 3, H335 STOT RE 2, H373

The product is classified as hazardous according to UK CLP Regulation SI 2019/720 as amended.

See Section 16 for the full text of the H statements declared above.

See Section 11 for more detailed information on health effects and symptoms.

2.2 Label elements

Code : 00168694 SIGMALINE 859 REP HARDE	Date of issue/Date of revision : 7 November 2022 NER
SECTION 2: Hazards	identification
Hazard pictograms	
Signal word	: Danger
Hazard statements	 Flammable liquid and vapour. Causes skin irritation. May cause an allergic skin reaction. Causes serious eye irritation. Harmful if inhaled. May cause allergy or asthma symptoms or breathing difficulties if inhaled. May cause respiratory irritation. Suspected of causing cancer. May cause damage to organs through prolonged or repeated exposure.
Precautionary statements	
Prevention	: Wear protective gloves, protective clothing and eye or face protection. Keep away from heat, hot surfaces, sparks, open flames and other ignition sources. No smoking. Do not breathe vapour.
Response	: IF INHALED: Remove person to fresh air and keep comfortable for breathing. If experiencing respiratory symptoms: Call a POISON CENTER or doctor.
Storage	: Not applicable.
Disposal	 Dispose of contents and container in accordance with all local, regional, national and international regulations. P280, P210, P260, P304 + P340, P342 + P311, P501
Supplemental label elements	: Contains isocyanates. May produce an allergic reaction.
Annex XVII - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles	: As from August 24 2023 adequate training is required before industrial or professional use.
Special packaging requirem	<u>ents</u>
Containers to be fitted with child-resistant fastenings	: Not applicable.
Tactile warning of danger	: Not applicable.
2.3 Other hazards	
Product meets the criteria for PBT or vPvB according to Regulation (EC) No. 1907/2006, Annex XIII	: This mixture does not contain any substances that are assessed to be a PBT or a vPvB.
Other hazards which do not result in classification	: Prolonged or repeated contact may dry skin and cause irritation.

SECTION 3: Composition/information on ingredients

Mixture

3.2 Mixtures

:

Code : 00168694 **SIGMALINE 859 REP HARDENER** **Date of issue/Date of revision** : 7 November 2022

SECTION 3: Composition/information on ingredients

Product/ingredient name	Identifiers	%	Classification	Туре
Toluene diisocyanate, oligomeric reaction products with 2,2'- oxydiethanol and propylidenetrimethanol	EC: 500-120-8 CAS: 53317-61-6	≥25 - ≤50	Eye Irrit. 2, H319 Skin Sens. 1, H317	[1]
Isocyanic acid, polymethylenepolyphenylene ester	REACH #: 01-2119457024-46 CAS: 9016-87-9	≥10 - ≤25	Acute Tox. 4, H332 Skin Irrit. 2, H315 Eye Irrit. 2, H319 Resp. Sens. 1, H334 Skin Sens. 1, H317 Carc. 2, H351 STOT SE 3, H335 STOT RE 2, H373 (inhalation)	[1] [2]
4,4'-methylenediphenyl diisocyanate	REACH #: 01-2119457014-47 EC: 202-966-0 CAS: 101-68-8 Index: 615-005-00-9	≥10 - ≤25	Àcute Tox. 4, H332 Skin Irrit. 2, H315 Eye Irrit. 2, H319 Resp. Sens. 1, H334 Skin Sens. 1, H317 Carc. 2, H351 STOT SE 3, H335 STOT RE 2, H373	[1] [2]
2-methoxy-1-methylethyl acetate	REACH #: 01-2119475791-29 EC: 203-603-9 CAS: 108-65-6 Index: 607-195-00-7	≥10 - <20	Flam. Liq. 3, H226 STOT SE 3, H336	[1] [2]
xylene	REACH #: 01-2119488216-32 EC: 215-535-7 CAS: 1330-20-7 Index: 601-022-00-9	≥5.0 - ≤10	Flam. Liq. 3, H226 Acute Tox. 4, H312 Acute Tox. 4, H332 Skin Irrit. 2, H315 Eye Irrit. 2, H319 STOT SE 3, H335 Asp. Tox. 1, H304	[1] [2]
o-(p-isocyanatobenzyl)phenyl isocyanate	REACH #: 01-2119480143-45 EC: 227-534-9 CAS: 5873-54-1 Index: 615-005-00-9	≥1.0 - ≤5.0	Acute Tox. 4, H332 Skin Irrit. 2, H315 Eye Irrit. 2, H319 Resp. Sens. 1, H334 Skin Sens. 1, H317 Carc. 2, H351 STOT SE 3, H335 STOT RE 2, H373	[1] [2]
ethylbenzene	REACH #: 01-2119489370-35 EC: 202-849-4 CAS: 100-41-4 Index: 601-023-00-4	≥1.0 - ≤5.0	Flam. Liq. 2, H225 Acute Tox. 4, H332 STOT RE 2, H373 (hearing organs) Asp. Tox. 1, H304 Aquatic Chronic 3, H412	[1] [2]
2,2'-methylenediphenyl diisocyanate	REACH #: 01-2119927323-43 EC: 219-799-4 CAS: 2536-05-2 Index: 615-005-00-9	<1.0	Acute Tox. 4, H332 Skin Irrit. 2, H315 Eye Irrit. 2, H319 Resp. Sens. 1, H334 Skin Sens. 1, H317 Carc. 2, H351 STOT SE 3, H335 STOT RE 2, H373	[1] [2]
m-tolylidene diisocyanate	REACH #: 01-2119454791-34 EC: 247-722-4 CAS: 26471-62-5 Index: 615-006-00-4	≤0.30	Acute Tox. 1, H330 Skin Irrit. 2, H315 Eye Irrit. 2, H319 Resp. Sens. 1, H334 Skin Sens. 1, H317	[1] [2]
English (GB)	United Kir	ngdom (UK)		3/19

Code : 00168694 SIGMALINE 859 REP HARDENER	Date of issue/Date of revision	: 7 November 2022
SECTION 3: Composition/infor	mation on ingredients	
	ST Aq	rc. 2, H351 OT SE 3, H335 uatic Chronic 3, 12
		e Section 16 for e full text of the H

There are no additional ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified as hazardous to health or the environment, are PBTs, vPvBs or Substances of equivalent concern, or have been assigned a workplace exposure limit and hence require reporting in this section. Xylene: Several REACH registrations cover the REACH registered substance with xylene isomers, ethylbenzene (and toluene). The other REACH Registrations include: 01-2119555267-33 reaction mass of ethylbenzene and m-xylene and p-xylene, 01-2119486136-34 Aromatic hydrocarbons, C8, 01-2119539452-40 reaction mass of ethylbenzene and xylene. Type

statements declared

above.

[1] Substance classified with a health or environmental hazard

[2] Substance with a workplace exposure limit

Occupational exposure limits, if available, are listed in Section 8.

SUB codes represent substances without registered CAS Numbers.

SECTION 4: First aid measures

4.1 Description of first aid measures

Eye contact	: Remove contact lenses, irrigate copiously with clean, fresh water, holding the eyelids apart for at least 10 minutes and seek immediate medical advice.
Inhalation	: Remove to fresh air. Keep person warm and at rest. If not breathing, if breathing is irregular or if respiratory arrest occurs, provide artificial respiration or oxygen by trained personnel.
Skin contact	: Remove contaminated clothing and shoes. Wash skin thoroughly with soap and water or use recognised skin cleanser. Do NOT use solvents or thinners.
Ingestion	: If swallowed, seek medical advice immediately and show the container or label. Keep person warm and at rest. Do NOT induce vomiting.
Protection of first-aiders	: No action shall be taken involving any personal risk or without suitable training. If it is suspected that fumes are still present, the rescuer should wear an appropriate mask or self-contained breathing apparatus. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation. Wash contaminated clothing thoroughly with water before removing it, or wear gloves.

4.2 Most important symptoms and effects, both acute and delayed

Potential acute health effects		
Eye contact	:	Causes serious eye irritation.
Inhalation	:	Harmful if inhaled. May cause respiratory irritation. May cause allergy or asthma symptoms or breathing difficulties if inhaled.
Skin contact	:	Causes skin irritation. Defatting to the skin. May cause an allergic skin reaction.
Ingestion	:	No known significant effects or critical hazards.
Over-exposure signs/sympto	on	<u>15</u>
Eye contact	:	Adverse symptoms may include the following: pain or irritation watering redness
Inhalation	:	Adverse symptoms may include the following: respiratory tract irritation coughing wheezing and breathing difficulties asthma

Code : 00168694 SIGMALINE 859 REP HARDI	Date of issue/Date of revision : 7 November 2022 ENER
SECTION 4: First aid	d measures
Skin contact	: Adverse symptoms may include the following: irritation redness dryness cracking
Ingestion	: No specific data.
4.3 Indication of any immed	iate medical attention and special treatment needed
Notes to physician	: In case of inhalation of decomposition products in a fire, symptoms may be delayed. The exposed person may need to be kept under medical surveillance for 48 hours.
Specific treatments	: No specific treatment.
SECTION 5: Firefigh	ting measures
5.1 Extinguishing media Suitable extinguishing media	: Use dry chemical, CO ₂ , water spray (fog) or foam.
Unsuitable extinguishing	: Do not use water jet.

5.2 Special hazards arising from the substance or mixture

media

Hazards from the substance or mixture	:	Flammable liquid and vapour. Runoff to sewer may create fire or explosion hazard. In a fire or if heated, a pressure increase will occur and the container may burst, with the risk of a subsequent explosion.
Hazardous combustion products	:	Decomposition products may include the following materials: carbon oxides nitrogen oxides Cyanate and isocyanate. hydrogen cyanide
5.3 Advice for firefighters		
Special protective actions for fire-fighters	:	Promptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or without suitable training. Move containers from fire area if this can be done without risk. Use water spray to keep fire-exposed containers cool.
Special protective equipment for fire-fighters	:	Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode.

SECTION 6: Accidental release measures

6.1 Personal precautions, pro	te	ctive equipment and emergency procedures
For non-emergency personnel	:	No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilt material. Shut off all ignition sources. No flares, smoking or flames in hazard area. Avoid breathing vapour or mist. Provide adequate ventilation. Wear appropriate respirator when ventilation is inadequate. Put on appropriate personal protective equipment.
For emergency responders	:	If specialised clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel".
6.2 Environmental precautions	:	Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air).

6.3 Methods and material for containment and cleaning up

English (GB)	United Kingdom (UK)	5/19
--------------	---------------------	------

J T) No. 1907/2006 (REACH), Annex II, as amended by UK REACH Regulation SI 2019/758
Code : 00168694 SIGMALINE 859 REP HAR	Date of issue/Date of revision : 7 November 2022 CDENER : 2022
SECTION 6: Accide	ental release measures
Small spill	: Stop leak if without risk. Move containers from spill area. Use spark-proof tools and explosion-proof equipment. Dilute with water and mop up if water-soluble. Alternatively, or if water-insoluble, absorb with an inert dry material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor.
Large spill	: Stop leak if without risk. Move containers from spill area. Use spark-proof tools and explosion-proof equipment. Approach the release from upwind. Prevent entry into sewers, water courses, basements or confined areas. Wash spillages into an effluent treatment plant or proceed as follows. Contain and collect spillage with non-combustible, absorbent material e.g. sand, earth, vermiculite or diatomaceous earth and place in container for disposal according to local regulations (see Section 13). Dispose of via a licensed waste disposal contractor. Contaminated absorbent material may pose the same hazard as the spilt product. Note: see Section 1 for emergency contact information and Section 13 for waste disposal.
Special provisions	: Contain and collect spillage with non-combustible, absorbent material e.g. sand, earth, vermiculite or diatomaceous earth and place in container for disposal according to local regulations (see Section 13). Place in a suitable container. The contaminated area should be cleaned immediately with a suitable decontaminant. One possible (flammable) decontaminant comprises (by volume): water (45 parts), ethanol or isopropyl alcohol (50 parts) and concentrated (d: 0,880) ammonia solution (5 parts). A non-flammable alternative is sodium carbonate (5 parts) and water (95 parts). Add the same decontaminant to the remnants and let stand for several days until no further reaction in an unsealed container. Once this stage is reached, close container and dispose of according to local regulations (see section 13). Do not allow to enter drains or watercourses. If the product contaminates lakes, rivers, or sewers, inform the appropriate authorities in accordance with local regulations.
6.4 Reference to other	: See Section 1 for emergency contact information.

sections

See Section 8 for information on appropriate personal protective equipment. See Section 13 for additional waste treatment information.

SECTION 7: Handling and storage

The information in this section contains generic advice and guidance. The list of Identified Uses in Section 1 should be consulted for any available use-specific information provided in the Exposure Scenario(s).

7.1 Precautions for safe handling

Protective measures	: Put on appropriate personal protective equipment (see Section 8). Persons with a history of skin sensitisation problems or asthma, allergies or chronic or recurrent respiratory disease should not be employed in any process in which this product is used. Avoid exposure - obtain special instructions before use. Do not handle until all safety precautions have been read and understood. Do not get in eyes or on skin or clothing. Do not breathe vapour or mist. Do not ingest. Use only with adequate ventilation. Wear appropriate respirator when ventilation is inadequate. Do not enter storage areas and confined spaces unless adequately ventilated. Keep in the original container or an approved alternative made from a compatible material, kept tightly closed when not in use. Store and use away from heat, sparks, open flame or any other ignition source. Use explosion-proof electrical (ventilating, lighting and material handling) equipment. Use only non-sparking tools. Take precautionary measures against electrostatic discharges. Empty containers retain product residue and can be hazardous. Do not reuse container.
Advice on general occupational hygiene	: Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures.

7.2 Conditions for safe storage, including any incompatibilities

Code : 00168694 SIGMALINE 859 REP HARDENER Date of issue/Date of revision

: 7 November 2022

SECTION 7: Handling and storage

Store between the following temperatures: 0 to 35°C (32 to 95°F). Store in accordance with local regulations. Store in a segregated and approved area. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Store locked up. Eliminate all ignition sources. Separate from oxidising materials. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabelled containers. Use appropriate containment to avoid environmental contamination. See Section 10 for incompatible materials before handling or use.

Precautions should be taken to minimise exposure to atmospheric humidity or water.

CO2 will be formed, which, in closed containers, could result in pressurisation.

7.3 Specific end use(s)

See Section 1.2 for Identified uses.

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

The information in this section contains generic advice and guidance. The list of Identified Uses in Section 1 should be consulted for any available use-specific information provided in the Exposure Scenario(s).

Occupational exposure limits

Product/ingredient name	Exposure limit values
lsocyanic acid, polymethylenepolyphenylene	EH40/2005 WELs (United Kingdom (UK), 1/2020). [isocyanates,
ester	all, except methyl isocyanate] Inhalation sensitiser.
	STEL: 0.07 mg/m ³ , (as -NCO) 15 minutes.
1.4' methylenedinhenyl diisesyanata	TWA: 0.02 mg/m ³ , (as -NCO) 8 hours.
4,4'-methylenediphenyl diisocyanate	EH40/2005 WELs (United Kingdom (UK), 1/2020). [isocyanates,
	all, except methyl isocyanate] Inhalation sensitiser.
	STEL: 0.07 mg/m³, (as -NCO) 15 minutes. TWA: 0.02 mg/m³, (as -NCO) 8 hours.
2 methows 1 methylethyl exetete	
2-methoxy-1-methylethyl acetate	EH40/2005 WELs (United Kingdom (UK), 1/2020). Absorbed
	through skin.
	STEL: 548 mg/m ³ 15 minutes.
	STEL: 100 ppm 15 minutes.
	TWA: 274 mg/m ³ 8 hours. TWA: 50 ppm 8 hours.
xylene	EH40/2005 WELs (United Kingdom (UK), 1/2020). [xylene, o-,m-,p
	or mixed isomers] Absorbed through skin.
	STEL: 441 mg/m ³ 15 minutes.
	STEL: 100 ppm 15 minutes.
	TWA: 220 mg/m ³ 8 hours.
	TWA: 50 ppm 8 hours.
o-(p-isocyanatobenzyl)phenyl isocyanate	EH40/2005 WELs (United Kingdom (UK), 1/2020). [isocyanates,
	all, except methyl isocyanate] Inhalation sensitiser.
	STEL: 0.07 mg/m ³ , (as -NCO) 15 minutes.
	TWA: 0.02 mg/m ³ , (as -NCO) 8 hours.
ethylbenzene	EH40/2005 WELs (United Kingdom (UK), 1/2020). Absorbed
	through skin.
	STEL: 552 mg/m ³ 15 minutes.
	STEL: 125 ppm 15 minutes.
	TWA: 441 mg/m ³ 8 hours.
	TWA: 100 ppm 8 hours.
2,2'-methylenediphenyl diisocyanate	EH40/2005 WELs (United Kingdom (UK), 1/2020). [isocyanates,
	all, except methyl isocyanate] Inhalation sensitiser.
	STEL: 0.07 mg/m ³ , (as -NCO) 15 minutes.
	TWA: 0.02 mg/m ³ , (as -NCO) 8 hours.
m-tolylidene diisocyanate	EH40/2005 WELs (United Kingdom (UK), 1/2020). [isocyanates,
	all, except methyl isocyanate] Inhalation sensitiser.
	STEL: 0.07 mg/m³, (as -NCO) 15 minutes.
English (GB)	United Kingdom (UK) 7/19

Code	: 00168694	Date of issue/Date of revision	: 7 November 2022
SIGMALINE	859 REP HARDENER		

SECTION 8: Exposure controls/personal protection

	TWA: 0.02 mg/m³, (as -NCO) 8 hours.
procedures at of pr st	his product contains ingredients with exposure limits, personal, workplace nosphere or biological monitoring may be required to determine the effectiveness the ventilation or other control measures and/or the necessity to use respiratory otective equipment. Reference should be made to appropriate monitoring andards. Reference to national guidance documents for methods for the termination of hazardous substances will also be required.

DNELs/DMELs

English (GB)

DNELShort term Dermal17.2 mg/cm2population [Consumers] general population [Consumers]Local population [Consumers]DNELLong term Inhalation0.025 mg/m3General population [Consumers]Systemi population [Consumers]DNELLong term Inhalation DNEL0.025 mg/m3General population [Consumers]Local Local DONELDNELLong term Inhalation DNEL0.025 mg/m3General population Local 0.05 mg/m3Local Local Local Local D.1 mg/m3Local Local	Product/ingredient name	Туре	Exposure	Value	Population	Effects
DNEL A.4'-methylenediphenyl diisocyanateDNEL DNELShort term Inhalation Long term Inhalation0.1 mg/m³ 0.025 mg/m³Workers General population [Consumers]] General population [Consumers]]Local population [Consumers]]4.4'-methylenediphenyl diisocyanateDNEL DNELShort term Inhalation DNEL0.05 mg/m³Workers General population [Consumers]]Local population [Consumers]]4.4'-methylenediphenyl diisocyanateDNEL DNELShort term Inhalation DNEL0.05 mg/m³Workers General population [Consumers]]Local Local population [Consumers]]DNEL DNELShort term Inhalation DNEL0.1 mg/m³ General DNELWorkers General Local population [Consumers]]Local Local population [Consumers]]DNEL DNELShort term Inhalation DNEL0.1 mg/m³ General Short term Dermal DNEL0.1 mg/m³ So mg/kg bw/day Short term Dermal 25 mg/kg bw/dayWorkers Workers Workers General Systemi population [Consumers]] General Systemi population [Consumers]]DNEL DNELShort term Oral20 mg/kg bw/day General Systemi population [Consumers]] General General Systemi population [Consumers]]Systemi population [Consumers]] General General Systemi population [Consumers]]DNEL DNELShort term Dermal DNEL17.2 mg/cm² General population [Consumers]] General General population [Consumers]]DNEL DNEL DNELLong term Inhalation DNEL0.025 mg/m³ General General	polymethylenepolyphenylene	DNEL	Long term Inhalation	0.05 mg/m ³	Workers	Local
4.4'-methylenediphenyl DNEL Long term Inhalation 0.025 mg/m³ General population [Consumers] 4.4'-methylenediphenyl DNEL Short term Inhalation 0.05 mg/m³ General population [Consumers] DNEL Long term Inhalation 0.05 mg/m³ Workers Local population [Consumers] DNEL Short term Inhalation 0.1 mg/m³ Workers Local population [Consumers] DNEL Short term Inhalation 0.1 mg/m³ Workers Local population [Consumers] DNEL Short term Inhalation 0.05 mg/m³ General population [Consumers] Local population [Consumers] DNEL Short term Inhalation 0.05 mg/m³ General population [Consumers] Local population [Consumers] DNEL Short term Inhalation 0.05 mg/m³ General population [Consumers] Local population [Consumers] DNEL Short term Dermal 28 mg/sdw/day Workers Systemi population [Consumers] DNEL Short term Dermal 20 mg/kg bw/day General population [Consumers] Systemi population [Consumers] DNEL Short term Oral 20 mg/kg bw/day General population [Consumers] Systemi population [Consumers] DNEL Short term Dermal 17.2 mg/cm² General population [Consumers] General population [Consumers]		DNEL	Short term Inhalation	0.1 mg/m^3	Workers	Local
4.4'-methylenediphenyl DNEL Short term Inhalation 0.05 mg/m³ population [Consumers] Local population [Consumers] 4.4'-methylenediphenyl diisocyanate DNEL Long term Inhalation DNEL 0.05 mg/m³ Workers Local DNEL DNEL Short term Inhalation DNEL 0.1 mg/m³ Workers Local DNEL Short term Inhalation DNEL 0.05 mg/m³ General General Local DNEL Short term Inhalation 0.05 mg/m³ General General Local DNEL Short term Inhalation 0.05 mg/m³ General General Local DNEL Short term Inhalation 0.05 mg/m³ General gopulation Local DNEL Short term Inhalation 0.05 mg/m³ Workers Systemi DNEL Short term Dermal 50 mg/kg bw/day Workers Systemi DNEL Short term Dermal 25 mg/kg bw/day General general Systemi DNEL Short term Oral 20 mg/kg bw/day General general Systemi DNEL Short term Oral 20 mg/kg bw/day General general Systemi DNEL Short term Dermal 17.2 mg/cm² General general Systemi DNEL Long term Inhalation 0.025 mg/m³ Genera						
4.4'-methylenediphenyl DNEL Short term Inhalation 0.05 mg/m³ [Consumers] General population [Consumers] Local 4.4'-methylenediphenyl DNEL Long term Inhalation 0.05 mg/m³ Workers Local DNEL DNEL Short term Inhalation 0.05 mg/m³ Workers Local DNEL Short term Inhalation 0.1 mg/m³ Workers Local DNEL Short term Inhalation 0.05 mg/m³ General Local DNEL Short term Inhalation 0.05 mg/m³ General Local DNEL Short term Inhalation 0.05 mg/m³ Workers Systemi DNEL Short term Inhalation 0.1 mg/m³ Workers Systemi DNEL Short term Dermal 28.7 mg/cm² Workers Systemi DNEL Short term Oral 20 mg/kg bw/day General Systemi DNEL Short term Oral 20 mg/kg bw/day General Systemi DNEL Short term Oral 20 mg/kg bw/day General Systemi DNEL Short term Inhalation 0.025 mg/m³ General Systemi			5	<u>-</u>		
4.4'-methylenediphenyl diisocyanate DNEL Short term Inhalation 0.05 mg/m³ General population [Consumers] Local DNEL DNEL Long term Inhalation 0.05 mg/m³ Workers Local DNEL Short term Inhalation 0.1 mg/m³ Workers Local DNEL Short term Inhalation 0.1 mg/m³ Workers Local DNEL Short term Inhalation 0.05 mg/m³ General population [Consumers] Local DNEL Short term Inhalation 0.05 mg/m³ Workers Systemi DNEL Short term Dermal 0.1 mg/m³ Workers Systemi DNEL Short term Dermal 0.5 mg/kg bw/day Workers Systemi DNEL Short term Dermal 25 mg/kg bw/day Workers Local DNEL Short term Inhalation 0.05 mg/m³ General population [Consumers] Systemi DNEL Short term Inhalation 0.05 mg/m³ General population [Consumers] Systemi DNEL Short term Inhalation 0.05 mg/m³ General population [Consumers] Systemi DNEL Short term Inhalation 0.025 mg/m³ </td <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>						
4,4'-methylenediphenyl diisocyanate DNEL Long term Inhalation 0.05 mg/m³ [Consumers] Workers Local DNEL Short term Inhalation 0.1 mg/m³ Workers Local DNEL Short term Inhalation 0.1 mg/m³ Workers Local DNEL Short term Inhalation 0.05 mg/m³ General population [Consumers] Local DNEL Short term Inhalation 0.05 mg/m³ General population [Consumers] Local DNEL Short term Inhalation 0.05 mg/m³ Workers Systemi DNEL Short term Dermal 50 mg/kg bw/day Workers Systemi DNEL Short term Dermal 28.7 mg/cm² Workers Systemi DNEL Short term Oral 0.05 mg/m³ General population [Consumers] Systemi DNEL Short term Oral 20 mg/kg bw/day General population [Consumers] Systemi DNEL Short term Inhalation 0.025 mg/m³ General population [Consumers] Local DNEL Short term Inhalation 0.025 mg/m³ General population [Consumers] Systemi DNEL Long term Inhalation DNEL <td< td=""><td></td><td>DNEL</td><td>Short term Inhalation</td><td>0.05 mg/m³</td><td></td><td>Local</td></td<>		DNEL	Short term Inhalation	0.05 mg/m ³		Local
4.4'-methylenediphenyl diisocyanate DNEL DNEL DNEL Long term Inhalation DNEL 0.05 mg/m³ Workers Local DNEL DNEL Short term Inhalation DNEL Short term Inhalation 0.1 mg/m³ Workers Local DNEL Short term Inhalation 0.05 mg/m³ General population [Consumers]] Local DNEL Short term Inhalation 0.05 mg/m³ General population Local DNEL Short term Inhalation 0.1 mg/m³ Workers Systemi DNEL Short term Inhalation 0.1 mg/m³ Workers Systemi DNEL Short term Dermal 28.7 mg/cm² Workers Systemi DNEL Short term Dermal 28.7 mg/cm² General population [Consumers]] Systemi DNEL Short term Oral 20 mg/kg bw/day General population [Consumers]] Systemi DNEL Short term Dermal 17.2 mg/cm² General population [Consumers]] Local DNEL Short term Inhalation DNEL Long term Inhalation DNEL 0.025 mg/m³ General population [Consumers]] Local DNEL Short term Inhalation DNEL Short term Inhalation DNEL 0.05 mg/m³					population	
diisocyanate DNEL Short term Inhalation DNEL 0.1 mg/m³ Workers Local DNEL Short term Inhalation 0.05 mg/m³ General Local DNEL Short term Inhalation 0.05 mg/m³ General Local DNEL Short term Inhalation 0.05 mg/m³ General Local DNEL Short term Inhalation 0.05 mg/m³ Workers Systemi DNEL Short term Dermal 0.1 mg/m³ Workers Systemi DNEL Short term Dermal 0.05 mg/m³ Workers Systemi DNEL Short term Dermal 0.05 mg/m³ Workers Systemi DNEL Short term Oral 0.05 mg/m³ General Systemi DNEL Short term Oral 0.05 mg/m³ General Systemi DNEL Short term Oral 20 mg/kg bw/day General Systemi DNEL Short term Inhalation 0.025 mg/m³ General Systemi DNEL Short term Inhalation 0.025 mg/m³ General Systemi DNEL Long term Inhalation 0.025 mg/m³ General<						
DNEL DNELShort term Inhalation Long term Inhalation0.1 mg/m³ 0.025 mg/m³Workers General population [Consumers]Local LocalDNEL DNELShort term Inhalation0.05 mg/m³General general Doulation [Consumers]Local population [Consumers]DNEL DNELShort term Inhalation DNEL0.05 mg/m³General WorkersLocal population [Consumers]DNEL DNELShort term Inhalation DNEL0.1 mg/m³WorkersSystemi population [Consumers]DNEL DNELShort term Dermal DNELShort term Dermal Short term Dermal28.7 mg/cm² 28.7 mg/cm²Workers General population [Consumers]DNEL DNELShort term Oral0.05 mg/m³General gopulation [Consumers]Systemi population [Consumers]DNEL DNELShort term Oral20 mg/kg bw/dayGeneral gopulation [Consumers]Systemi population [Consumers]DNEL DNELShort term Dermal17.2 mg/cm²General gopulation [Consumers]Systemi population [Consumers]DNEL DNELLong term Inhalation DNEL0.025 mg/m³General general population [Consumers]Systemi population [Consumers]DNEL DNELLong term Inhalation DNEL0.025 mg/m³General population [Consumers]DNEL DNELLong term Inhalation DNEL0.05 mg/m³General population [Consumers]DNEL DNELLong term Inhalation DNEL0.05 mg/m³General population [Consumers]DNEL DNEL <td< td=""><td></td><td>DNEL</td><td>Long term Inhalation</td><td>0.05 mg/m³</td><td>Workers</td><td>Local</td></td<>		DNEL	Long term Inhalation	0.05 mg/m³	Workers	Local
DNELLong term Inhalation0.025 mg/m³General population [Consumers]Local population [Consumers]DNELShort term Inhalation0.05 mg/m³General population [Consumers]Local population [Consumers]DNELShort term Inhalation0.1 mg/m³WorkersSystemi population [Consumers]DNELShort term Dermal50 mg/kg bw/dayWorkersSystemi population [Consumers]DNELShort term Dermal25 mg/kg bw/dayGeneral generalSystemi population [Consumers]DNELShort term Inhalation0.05 mg/m³General 	diisocyanate					
DNELShort term Inhalation0.05 mg/m³population [Consumers] general population [Consumers]LocalDNELShort term Inhalation DNEL0.1 mg/m³WorkersSystemi population [Consumers]DNELShort term Inhalation DNEL0.1 mg/m³WorkersSystemi population [Consumers]DNELShort term Dermal DNELShort term Dermal28.7 mg/cm²WorkersSystemi population [Consumers]DNELShort term Inhalation0.05 mg/m³General gopulation [Consumers]Systemi population [Consumers]DNELShort term Oral20 mg/kg bw/dayGeneral gopulation [Consumers]Systemi population [Consumers]DNELShort term Oral20 mg/kg bw/dayGeneral gopulation [Consumers]Systemi population [Consumers]DNELShort term Dermal17.2 mg/cm²General gopulation [Consumers]Systemi population [Consumers]DNELShort term Inhalation0.025 mg/m³General general population [Consumers]Systemi population [Consumers]DNELLong term Inhalation DNEL0.025 mg/m³General population General population [Consumers]Local LocalDNELLong term Inhalation DNEL0.025 mg/m³General population Local LocalLocal LocalDNELShort term Inhalation DNEL0.05 mg/m³General population Local LocalLocal Local						
DNEL DNELShort term Inhalation DNEL DN		DNEL	Long term Inhalation	0.025 mg/m ³		Local
DNEL DNELShort term Inhalation Inhalation0.05 mg/m³General population [Consumers]LocalDNEL DNELShort term Inhalation DNEL0.1 mg/m³WorkersSystemiDNEL DNELShort term Dermal DNEL50 mg/kg bw/dayWorkersSystemiDNEL DNELShort term Dermal DNEL28.7 mg/cm²WorkersLocalDNEL DNELShort term Dermal DNEL25 mg/kg bw/dayWorkersSystemiDNEL DNELShort term Inhalation0.05 mg/m³General population [Consumers]SystemiDNEL DNELShort term Oral20 mg/kg bw/dayGeneral population [Consumers]Systemi population [Consumers]DNEL DNELShort term Dermal17.2 mg/cm²General gopulation [Consumers]Systemi population [Consumers]DNEL DNELLong term Inhalation DNEL0.025 mg/m³General gopulation [Consumers]Systemi population [Consumers]DNEL DNELLong term Inhalation DNEL0.05 mg/m³General general population [Consumers]Systemi population [Consumers]DNEL DNELLong term Inhalation DNEL0.05 mg/m³General population [Consumers]Local Local LocalDNEL DNEL DNELLong term Inhalation DNEL0.05 mg/m³General population Local Local LocalLocal Local						
DNEL DNEL DNELShort term Inhalation DNEL Short term Dermal DNEL0.1 mg/m³ Users Systemi Somg/m³population [Consumers] Workers Workers Workers Workers Systemi population [Consumers]DNEL DNELShort term Dermal DNEL0.05 mg/m³ Somg/kg bw/day Short term Dermal 28.7 mg/cm²Workers Workers Workers Users Down Local Local Down [Consumers]Systemi population [Consumers] General population [Consumers]DNEL DNELShort term Oral0.05 mg/m³ General population [Consumers]Systemi population [Consumers]DNEL DNELShort term Oral20 mg/kg bw/day (General population [Consumers]]Systemi population [Consumers]DNEL DNELShort term Dermal17.2 mg/cm² General population [Consumers]]Local population [Consumers]DNEL DNEL DNELLong term Inhalation DNEL DNEL Long term Inhalation0.025 mg/m³ General population [Consumers]Systemi population [Consumers]DNEL DNEL DNEL DNEL Long term Inhalation0.025 mg/m³ O.025 mg/m³ General population [Consumers]Local Local LocalDNEL DNEL DNEL DNEL DNEL DNEL Short term Inhalation0.025 mg/m³ O.05 mg/m³ General population General population [Consumers] General population [Consumers] General population [Consumers]Local Local LocalDNEL DNEL DNEL DNEL Short term Inhalation0.05 mg/m³ O.05 mg/m³ General population General population [Cocal General population [Consumers] <td></td> <td></td> <td></td> <td>0.05</td> <td></td> <td></td>				0.05		
DNEL DNEL DNEL DNEL DNEL DNEL DNELShort term Inhalation Long term Inhalation DNEL Short term Dermal0.1 mg/m³ 0.05 mg/m³[Consumers] Workers Workers Workers Workers Systemi Downders Systemi population [Consumers]DNEL DNELShort term Dermal Short term Dermal0.1 mg/m³ 0.05 mg/m³Workers Workers Uorkers General population [Consumers]Systemi population [Consumers]DNEL DNELShort term Inhalation0.05 mg/m³General population [Consumers]Systemi population [Consumers]DNEL DNELShort term Oral20 mg/kg bw/dayGeneral gopulation [Consumers]Systemi population [Consumers]DNEL DNELShort term Dermal17.2 mg/cm²General gopulation [Consumers]Systemi population [Consumers]DNEL DNELLong term Inhalation DNEL0.025 mg/m³General gopulation [Consumers]Systemi population [Consumers]DNEL DNEL DNELLong term Inhalation DNEL DNEL DNEL0.025 mg/m³General general population [Consumers]DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL Cong term Inhalation DNEL DNEL Short term Inhalation DNEL DNEL DNEL DNEL DNEL Short term Inhalation DNEL DNEL DNEL DNEL Short term Inhalation DNEL DNEL DNEL DNEL Short term Inhalation DNEL DN		DNEL	Short term Innalation	0.05 mg/m ³	-	Local
DNEL DNEL DNEL DNEL DNEL DNEL DNELShort term Inhalation Dermal DNEL DNEL DNEL0.1 mg/m³ 0.05 mg/m³Workers WorkersSystemi Systemi Systemi Som g/kg bw/dayDNEL DNELShort term Dermal DNEL28.7 mg/cm² 25 mg/kg bw/dayWorkers General population [Consumers]Systemi population [Consumers]DNEL DNELShort term Inhalation NEL0.05 mg/m³General General population [Consumers]Systemi population [Consumers]DNEL DNELShort term Oral20 mg/kg bw/dayGeneral General population [Consumers]Systemi population [Consumers]DNEL DNELShort term Dermal17.2 mg/cm²General General population [Consumers]Systemi population [Consumers]DNEL DNEL DNELLong term Inhalation DNEL <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>						
DNEL DNEL DNELLong term Inhalation DNEL 			Short torm Inholation	0.1 mg/m^3		Svetemie
DNEL DNEL DNELShort term Dermal Short term Dermal50 mg/kg bw/day 28.7 mg/cm2Workers WorkersSystemi LocalDNEL DNELShort term Dermal25 mg/kg bw/dayGeneral opulation [Consumers]Systemi population [Consumers]DNEL DNELShort term Inhalation0.05 mg/m3General opulation [Consumers]Systemi population [Consumers]DNEL DNELShort term Oral20 mg/kg bw/dayGeneral opulation [Consumers]Systemi population [Consumers]DNEL DNELShort term Dermal17.2 mg/cm2General population [Consumers]Systemi population [Consumers]DNEL DNELLong term Inhalation DNEL0.025 mg/m3General general population [Consumers]Systemi population [Consumers]DNEL DNELLong term Inhalation DNEL0.025 mg/m3General general population [Consumers]Local Local Local Local 0.055 mg/m3DNEL DNEL DNELShort term Inhalation DNEL0.025 mg/m3General population Local Local Local 0.055 mg/m3Local Local Local Local Local Local Local Local Local Local Local						
DNEL DNELShort term Dermal Short term Dermal28.7 mg/cm² 25 mg/kg bw/dayWorkers General population [Consumers]Local Systemi population [Consumers]DNELShort term Inhalation0.05 mg/m³General general population [Consumers]Systemi population [Consumers]DNELShort term Oral20 mg/kg bw/dayGeneral general population [Consumers]Systemi population [Consumers]DNELShort term Oral20 mg/kg bw/dayGeneral general population [Consumers]Systemi population [Consumers]DNELShort term Dermal17.2 mg/cm²General general population [Consumers]Local Local Local population [Consumers]DNELLong term Inhalation DNEL0.025 mg/m³General general population Local Local Local Local Local Local 0.05 mg/m³Systemi population [Consumers]DNELLong term Inhalation DNEL DNEL0.025 mg/m³ General population Local Local Local Local 0.05 mg/m³General population General population Local Local Local Local Local Local						
DNELShort term Dermal25 mg/kg bw/dayGeneral population [Consumers]Systemi population [Consumers]DNELShort term Inhalation0.05 mg/m³General population [Consumers]Systemi population [Consumers]DNELShort term Oral20 mg/kg bw/dayGeneral gopulation [Consumers]Systemi population [Consumers]DNELShort term Dermal17.2 mg/cm²General gopulation [Consumers]Local population [Consumers]DNELShort term Inhalation0.025 mg/m³General gopulation [Consumers]Systemi population [Consumers]DNELLong term Inhalation DNEL0.025 mg/m³General gopulation [Consumers]Systemi population [Consumers]DNELLong term Inhalation DNEL0.025 mg/m³General population Local U.055 mg/m³Local Local Local LocalDNELDNEL DNELLong term Inhalation DNEL DNEL0.05 mg/m³ Uork term Inhalation U.055 mg/m³WorkersLocal						
DNELShort term Inhalation0.05 mg/m³population [Consumers] General population [Consumers]DNELShort term Oral20 mg/kg bw/dayGeneral general population [Consumers]Systemi population [Consumers]DNELShort term Oral20 mg/kg bw/dayGeneral general population [Consumers]Systemi population [Consumers]DNELShort term Dermal17.2 mg/cm²General general population [Consumers]Local population [Consumers]DNELLong term Inhalation0.025 mg/m³General population [Consumers]Systemi population [Consumers]DNELLong term Inhalation DNEL0.025 mg/m³General population Local 0.05 mg/m³Local Local Local Local Local 0.05 mg/m³						
DNELShort term Inhalation0.05 mg/m³[Consumers] General population [Consumers]]Systemi population [Consumers]]DNELShort term Oral20 mg/kg bw/dayGeneral general population [Consumers]]Systemi population [Consumers]]DNELShort term Dermal17.2 mg/cm²General population [Consumers]]Local population [Consumers]]DNELLong term Inhalation0.025 mg/m³General population [Consumers]]Systemi population [Consumers]]DNELLong term Inhalation0.025 mg/m³General population [Consumers]]Local Local Local Local 0.05 mg/m³DNELDNELLong term Inhalation DNEL0.05 mg/m³General population Local Local LocalLocal Local			Chort term Derman	20 mg/kg bw/day		Oysternie
DNELShort term Inhalation0.05 mg/m³General population [Consumers]]Systemi population [Consumers]]DNELShort term Oral20 mg/kg bw/dayGeneral population [Consumers]]Systemi population [Consumers]]DNELShort term Dermal17.2 mg/cm²General population [Consumers]]Local population [Consumers]]DNELLong term Inhalation0.025 mg/m³General population [Consumers]]Systemi population [Consumers]]DNELLong term Inhalation0.025 mg/m³General population [Consumers]]Local Local Local Local LocalDNELLong term Inhalation DNEL0.05 mg/m³General population Local Local Local Local Local LocalLocal Local						
DNELShort term Oral20 mg/kg bw/daypopulation [Consumers]DNELShort term Dermal17.2 mg/cm²General population [Consumers]Local population [Consumers]DNELShort term Inhalation0.025 mg/m³General population [Consumers]Systemi population [Consumers]DNELLong term Inhalation DNEL0.025 mg/m³General population [Consumers]Systemi population [Consumers]DNELLong term Inhalation DNEL0.025 mg/m³General population [Consumers]Local population [Consumers]DNELShort term Inhalation DNEL0.05 mg/m³General population Local U.05 mg/m³Local Vorkers		DNEL	Short term Inhalation	0.05 mg/m ³		Systemic
DNELShort term Oral20 mg/kg bw/day[Consumers] General population [Consumers]Systemi population [Consumers]DNELShort term Dermal17.2 mg/cm²General general population [Consumers]Local population [Consumers]DNELLong term Inhalation0.025 mg/m³General general population [Consumers]Systemi population [Consumers]DNELLong term Inhalation DNEL0.025 mg/m³General population General population [Consumers]Systemi population [Consumers]DNELLong term Inhalation DNEL0.025 mg/m³General population General population Local 0.05 mg/m³Local General population Local Local Workers				0.00		-)
DNELShort term Oral20 mg/kg bw/dayGeneral population [Consumers]Systemi population [Consumers]DNELShort term Dermal17.2 mg/cm²General population [Consumers]Local population [Consumers]DNELLong term Inhalation0.025 mg/m³General population [Consumers]Systemi population [Consumers]DNELLong term Inhalation0.025 mg/m³General population [Consumers]Systemi population [Consumers]DNELLong term Inhalation0.025 mg/m³General population (Consumers]Local Local LocalDNELShort term Inhalation DNEL0.05 mg/m³General population Local UnstructureLocal LocalDNELShort term Inhalation DNEL0.1 mg/m³WorkersLocal						
DNELShort term Dermal17.2 mg/cm2population [Consumers]Local population [Consumers]DNELLong term Inhalation0.025 mg/m3General population [Consumers]Systemi population [Consumers]DNELLong term Inhalation0.025 mg/m3General population [Consumers]Systemi population [Consumers]DNELLong term Inhalation DNEL0.025 mg/m3General population [Consumers]Local Local Local LocalDNELShort term Inhalation DNEL0.05 mg/m3General population Local Local 0.05 mg/m3Local Local Local		DNEL	Short term Oral	20 mg/kg bw/day		Systemic
DNELShort term Dermal17.2 mg/cm²General population [Consumers]Local population [Consumers]DNELLong term Inhalation0.025 mg/m³General population [Consumers]Systemi population [Consumers]DNELLong term Inhalation0.025 mg/m³General population [Consumers]Local Local Doted DNELDNELLong term Inhalation0.025 mg/m³General population Local U.CosLocal LocalDNELShort term Inhalation DNEL0.05 mg/m³General population Local U.CosLocal LocalDNELShort term Inhalation DNEL0.05 mg/m³WorkersLocal					population	-
DNELLong term Inhalation0.025 mg/m³population [Consumers] opulation [Consumers]Systemi population [Consumers]DNELLong term Inhalation0.025 mg/m³General population [Consumers]Systemi population Local DNELDNELShort term Inhalation0.05 mg/m³General population Local UnstructureLocal Local Local DNELDNELShort term Inhalation0.05 mg/m³WorkersLocal LocalDNELShort term Inhalation0.1 mg/m³WorkersLocal					[Consumers]	
DNELLong term Inhalation0.025 mg/m³[Consumers] General population [Consumers]Systemi population [Consumers]DNELLong term Inhalation0.025 mg/m³General population General population Local DNELLong term Inhalation0.05 mg/m³General population Local UnstructureLocal Local Local DNELDNELLong term Inhalation0.05 mg/m³General population Local Local Local DNELLocal Local		DNEL	Short term Dermal	17.2 mg/cm ²	General	Local
DNELLong term Inhalation0.025 mg/m³General population [Consumers]]Systemi population [Consumers]]DNELLong term Inhalation0.025 mg/m³General population General populationLocal LocalDNELShort term Inhalation0.05 mg/m³General population UnstructureLocal LocalDNELLong term Inhalation0.05 mg/m³WorkersLocal LocalDNELShort term Inhalation0.1 mg/m³WorkersLocal						
DNELLong term Inhalation0.025 mg/m³population [Consumers]DNELShort term Inhalation0.05 mg/m³General populationLocalDNELLong term Inhalation0.05 mg/m³WorkersLocalDNELShort term Inhalation0.01 mg/m³WorkersLocal						_
DNELLong term Inhalation0.025 mg/m³[Consumers]DNELShort term Inhalation0.05 mg/m³General populationLocalDNELLong term Inhalation0.05 mg/m³WorkersLocalDNELShort term Inhalation0.01 mg/m³WorkersLocal		DNEL	Long term Inhalation	0.025 mg/m³		Systemic
DNELLong term Inhalation0.025 mg/m³General populationLocalDNELShort term Inhalation0.05 mg/m³General populationLocalDNELLong term Inhalation0.05 mg/m³WorkersLocalDNELShort term Inhalation0.1 mg/m³WorkersLocal						
DNELShort term Inhalation0.05 mg/m³General populationLocalDNELLong term Inhalation0.05 mg/m³WorkersLocalDNELShort term Inhalation0.1 mg/m³WorkersLocal				0.005		
DNELLong term Inhalation0.05 mg/m³WorkersLocalDNELShort term Inhalation0.1 mg/m³WorkersLocal			-			
DNEL Short term Inhalation 0.1 mg/m ³ Workers Local						
La motiony a motivation with the second term (Trol 1.1.67 mailed buildov 1.1.2 operation) Systemi	2 mothows 1 mothylathyl	DNEL		1.67 mg/kg bw/day		
2-methoxy-1-methylethyl DNEL Long term Oral 1.67 mg/kg bw/day General population Systemi		DINEL	Long term Oral	1.07 mg/kg bw/day	General population	Systemic
DNEL Long term Inhalation 33 mg/m ³ General population Local		DNEL	Long term Inhalation	33 mg/m³	General population	Local
						Systemic
						Systemic
		DNEL				Systemic
DNEL Long term Inhalation 275 mg/m ³ Workers Systemi					Workers	Systemic
DNEL Short term Inhalation 550 mg/m ³ Workers Local					Workers	Local
	xylene					Systemic
DNEL Short term Inhalation 260 mg/m ³ General population Local		DNEL	Short term Inhalation	260 mg/m ³	General population	Local

United Kingdom (UK)

8/19

Code : 00168694 **SIGMALINE 859 REP HARDENER** **Date of issue/Date of revision** : 7 November 2022

SECTION 8: Exposure controls/personal protection

	DNEL	Long term Dermal	125 mg/kg bw/day	General population	Systemic
	DNEL	Long term Inhalation	65.3 mg/m ³	General population	Systemic
	DNEL	Long term Oral	12.5 mg/kg bw/day	General population	Systemic
	DNEL	Long term Inhalation	221 mg/m ³	Workers	Systemic
	DNEL	Short term Inhalation	442 mg/m ³	Workers	Systemic
			0		-
	DNEL	Long term Inhalation	221 mg/m ³	Workers	Local
	DNEL	Short term Inhalation	442 mg/m ³	Workers	Local
	DNEL	Long term Dermal	212 mg/kg bw/day	Workers	Systemic
	DNEL	Long term Inhalation	65.3 mg/m ³	General population	Local
	DNEL	Short term Inhalation	260 mg/m ³	General population	Local
	DNEL	Short term Inhalation	260 mg/m³	General population	Systemic
	DNEL	Long term Inhalation	221 mg/m³	Workers	Local
o-(p-isocyanatobenzyl)phenyl	DNEL	Short term Dermal	28.7 mg/cm ²	Workers	Local
isocyanate			Ŭ		
	DNEL	Long term Inhalation	0.025 mg/m ³	General population	Local
	DNEL	Long term Inhalation	0.025 mg/m ³	General population	Systemic
	DNEL	Short term Inhalation	0.05 mg/m ³	General population	Local
	DNEL	Short term Inhalation	0.05 mg/m ³	General population	Systemic
	DNEL	Long term Inhalation	0.05 mg/m ³	Workers	Local
	DNEL	Long term Inhalation	0.05 mg/m ³	Workers	Systemic
	DNEL	Short term Inhalation	0.1 mg/m ³	Workers	Local
	DNEL				
		Short term Inhalation	0.1 mg/m ³	Workers	Systemic
	DNEL	Short term Oral	20 mg/kg bw/day	General population	Systemic
	DNEL	Short term Dermal	25 mg/kg bw/day	General population	Systemic
	DNEL	Short term Dermal	50 mg/kg bw/day	Workers	Systemic
	DNEL	Short term Dermal	17.2 mg/cm ²	General population	Local
	DNEL	Short term Dermal	28.7 mg/cm ²	Workers	Local
ethylbenzene	DNEL	Long term Oral	1.6 mg/kg bw/day	General population	Systemic
-	DNEL	Long term Inhalation	15 mg/m ³	General population	Systemic
	DNEL	Long term Inhalation	77 mg/m ³	Workers	Systemic
	DNEL	Long term Dermal	180 mg/kg bw/day	Workers	Systemic
	DNEL	Short term Inhalation	293 mg/m ³	Workers	Local
2,2'-methylenediphenyl diisocyanate	DNEL	Short term Dermal	28.7 mg/cm ²	Workers	Local
anooganato	DNEL	Long term Inhalation	0.025 mg/m ³	General population	Local
	DNEL	Long term Inhalation	0.025 mg/m ³	General population	Systemic
	DNEL	Short term Inhalation	0.05 mg/m ³	General population	Local
	DNEL	Short term Inhalation	0.05 mg/m ³	General population	
	DNEL				-
		Long term Inhalation	0.05 mg/m ³	Workers	Local
	DNEL	Long term Inhalation	0.05 mg/m ³	Workers	Systemic
	DNEL	Short term Inhalation	0.1 mg/m ³	Workers	Local
	DNEL	Short term Inhalation	0.1 mg/m ³	Workers	Systemic
	DNEL	Short term Oral	20 mg/kg bw/day	General population	Systemic
	DNEL	Short term Dermal	25 mg/kg bw/day	General population	Systemic
	DNEL	Short term Dermal	50 mg/kg bw/day	Workers	Systemic
	DNEL	Short term Dermal	17.2 mg/cm ²	General population	Local
	DNEL	Short term Dermal	28.7 mg/cm ²	Workers	Local
m-tolylidene diisocyanate	DNEL	Long term Inhalation	0.035 mg/m ³	Workers	Local
	DNEL	Long term Inhalation	0.035 mg/m ³	Workers	Systemic
	DNEL	Short term Inhalation	0.035 mg/m ³	Workers	Local
	DNEL	Short term Inhalation	0.14 mg/m ³	Workers	Systemic

PNECs

Code : 00168694 SIGMALINE 859 REP HARDENER

Date of issue/Date of revision : 7 November 2022

SECTION 8: Exposure controls/personal protection

Product/ingredient name	Compartment Detail	Value	Method Detail
Isocyanic acid, polymethylenepolyphenylene ester	Fresh water	1 mg/l	Assessment Factors
	Marine water	0.1 mg/l	Assessment Factors
	Sewage Treatment Plant	1 mg/l	Assessment Factors
	Soil	1 mg/kg dwt	Assessment Factors
4,4'-methylenediphenyl diisocyanate	Fresh water	1 mg/l	Assessment Factors
	Marine water	0.1 mg/l	Assessment Factors
	Sewage Treatment Plant		Assessment Factors
	Soil	1 mg/kg dwt	Assessment Factors
2-methoxy-1-methylethyl acetate	Fresh water	0.635 mg/l	-
	Marine water	0.0635 mg/l	-
	Fresh water sediment	3.29 mg/kg	-
	Marine water sediment	0.329 mg/kg	-
	Soil	0.29 mg/kg	-
	Sewage Treatment Plant	100 mg/l	-
xylene	Fresh water	0.327 mg/l	-
	Marine water	0.327 mg/l	-
	Sewage Treatment Plant	6.58 mg/l	-
	Fresh water sediment	12.46 mg/kg dwt	-
	Marine water sediment	12.46 mg/kg dwt	-
	Soil	2.31 mg/kg	-
o-(p-isocyanatobenzyl)phenyl isocyanate	Fresh water	1 mg/l	Assessment Factors
	Marine water	0.1 mg/l	Assessment Factors
	Sewage Treatment Plant	1 mg/l	Assessment Factors
	Soil	1 mg/kg dwt	Equilibrium Partitioning
ethylbenzene	Fresh water	0.1 mg/l	Assessment Factors
	Marine water	0.01 mg/l	Assessment Factors
	Sewage Treatment Plant	9.6 mg/l	Assessment Factors
	Fresh water sediment	13.7 mg/kg dwt	Equilibrium Partitioning
	Marine water sediment	1.37 mg/kg dwt	Equilibrium Partitioning
	Soil	2.68 mg/kg dwt	Equilibrium Partitioning
	Secondary Poisoning	20 mg/kg	-
2,2'-methylenediphenyl diisocyanate	Fresh water	1 mg/l	Assessment Factors
	Marine water	0.1 mg/l	Assessment Factors
	Sewage Treatment Plant	1 mg/l	Assessment Factors
	Soil	1 mg/kg dwt	Assessment Factors
m-tolylidene diisocyanate	Fresh water	0.013 mg/l	Assessment Factors
•	Marine water	0.00125 mg/l	Assessment Factors
	Sewage Treatment Plant		Assessment Factors
	Soil	1 mg/kg dwt	Equilibrium Partitioning

8.2 Exposure controls

Appropriate engineering controls	: Use only with adequate ventilation. Use process enclosures, local exhaust ventilation or other engineering controls to keep worker exposure to airborne contaminants below any recommended or statutory limits. The engineering controls also need to keep gas, vapour or dust concentrations below any lower explosive limits. Use explosion-proof ventilation equipment.
Individual protection measur	<u>es</u>
Hygiene measures	: Wash hands, forearms and face thoroughly after handling chemical products, before eating, smoking and using the lavatory and at the end of the working period. Appropriate techniques should be used to remove potentially contaminated clothing. Contaminated work clothing should not be allowed out of the workplace. Wash contaminated clothing before reusing. Ensure that eyewash stations and safety showers are close to the workstation location.
Eye/face protection Skin protection	: Chemical splash goggles.
Hand protection	

Code : 00168694 SIGMALINE 859 REP HARDENER Date of issue/Date of revision

: 7 November 2022

SECTION 8: Exposure controls/personal protection

•	• •
	Chemical-resistant, impervious gloves complying with an approved standard should be worn at all times when handling chemical products if a risk assessment indicates this is necessary. Considering the parameters specified by the glove manufacturer, check during use that the gloves are still retaining their protective properties. It should be noted that the time to breakthrough for any glove material may be different for different glove manufacturers. In the case of mixtures, consisting of several substances, the protection time of the gloves cannot be accurately estimated. When prolonged or frequently repeated contact may occur, a glove with a protection class of 6 (breakthrough time greater than 480 minutes according to EN 374) is recommended. When only brief contact is expected, a glove with a protection class of 2 or higher (breakthrough time greater than 30 minutes according to EN 374) is recommended. The user must check that the final choice of type of glove selected for handling this product is the most appropriate and takes into account the particular conditions of use, as included in the user's risk assessment. butyl rubber
Body protection	: Personal protective equipment for the body should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product. When there is a risk of ignition from static electricity, wear antistatic protective clothing. For the greatest protection from static discharges, clothing should include anti-static overalls, boots and gloves.
Other skin protection	: Appropriate footwear and any additional skin protection measures should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.
Respiratory protection	: Use an air-fed respirator unless a site-specific assessment determines that an air-fed respirator is not necessary, in which case the results of the risk assessment should be utilized to determine whether respiratory protection is necessary and what type of protection is appropriate. Respirator selection must be based on known or anticipated exposure levels, the hazards of the product and the safe working limits of the selected respirator. If workers are exposed to concentrations above the exposure limit, they must use appropriate, certified respirators. Use a properly fitted, air-purifying or air-fed respirator complying with an approved standard if a risk assessment indicates this is necessary. Wear a respirator conforming to EN140. Filter type: organic vapour (Type A) and particulate filter P3
Restrictions on use	 Persons with a history of asthma, allergies or chronic or recurrent respiratory disease should not be employed in any process in which this product is used.
Environmental exposure controls	: Emissions from ventilation or work process equipment should be checked to ensure they comply with the requirements of environmental protection legislation. In some cases, fume scrubbers, filters or engineering modifications to the process equipment will be necessary to reduce emissions to acceptable levels.

SECTION 9: Physical and chemical properties

The conditions of measurement of all properties are at standard temperature and pressure unless otherwise indicated.

9.1 Information on basic physical and chemical properties

Appearance		
Physical state	: Liquid.	
Colour	: Not available.	
Odour	: Characteristic.	
Odour threshold	: Not available.	
Melting point/freezing point	 May start to solidify at the following temperature: -66°C (-86.8°F) This is based or data for the following ingredient: 2-methoxy-1-methylethyl acetate. Weighted average: -80.62°C (-113.1°F) 	ı
Initial boiling point and boiling range	: >37.78°C (>100°F)	
Flammability (solid, gas)	: liquid	
Upper/lower flammability or explosive limits	: Greatest known range: Lower: 0.8% Upper: 6.7% (xylene)	
Flash point	: Closed cup: 32°C (89.6°F)	
English (GB)	United Kingdom (UK) 11/19	,

Code	: 00168694	Date of issue/Date of revision	: 7 November 2022
SIGMALINE 8	359 REP HARDENER		

SECTION 9: Physical and chemical properties

Auto-ignition temperature : Ingredient name °C °F Method 2-methoxy-1-methylethyl acetate 333 631.4 DIN 51794 Decomposition temperature : pH : Not applicable.

:	Not applicable.
	Not applicable. insoluble in water.
:	Kinematic (room temperature): >400
	Kinematic (40°C): >21 mm²/s

Solubility(ies)

Viscosity

Solubility(les)		Method
Media	Result	
cold water	Not soluble	

mm²/s

1

Miscible with water : No.

Partition coefficient: n-octanol/ : Not applicable. water

÷

Vapour pressure

	Vapour Pressure at 20°C			V	Vapour pressure at 50°C	
Ingredient name	mm Hg	kPa	Method	mm Hg	kPa	
ethylbenzene	9.3	1.2				
Relative density	: 1.18	3	I	Į		
Vapour density	•	nest known rage: 4.15	,	1) (2-methoxy-	1-methylethyl acetate). Weighted	
Explosive properties	: The product itself is not explosive, but the formation of an explosible mixture of vapour or dust with air is possible.					
Oxidising properties	: Pro	duct does n	ot present an oxid	izing hazard.		
Particle characteristics						
Median particle size	: Not	applicable.				

SECTION 10: Stability and reactivity

10.1 Reactivity	: No specific test data related to reactivity available for this product or its ingredients.
10.2 Chemical stability	: The product is stable.
10.3 Possibility of hazardous reactions	: Under normal conditions of storage and use, hazardous reactions will not occur.
10.4 Conditions to avoid	In a fire, hazardous decomposition products may be produced. Refer to protective measures listed in sections 7 and 8.
10.5 Incompatible materials	: Keep away from: oxidising agents, strong alkalis, strong acids, amines, alcohols, water. Uncontrolled exothermic reactions occur with amines and alcohols.
10.6 Hazardous decomposition products	: Depending on conditions, decomposition products may include the following materials: Cyanate and isocyanate. carbon oxides nitrogen oxides hydrogen cyanide

- Code : 00168694 SIGMALINE 859 REP HARDENER
- Date of issue/Date of revision

: 7 November 2022

SECTION 11: Toxicological information

11.1 Information on toxicological effects

Acute toxicity

Product/ingredient name	Result	Species	Dose	Exposure
Toluene diisocyanate, oligomeric reaction products with 2,2'- oxydiethanol and propylidenetrimethanol	LD50 Oral	Rat	>5000 mg/kg	-
Isocyanic acid, polymethylenepolyphenylene ester	LD50 Dermal	Rabbit	>9400 mg/kg	-
	LD50 Oral	Rat	49 g/kg	-
4,4'-methylenediphenyl diisocyanate	LD50 Oral	Rat	9200 mg/kg	-
2-methoxy-1-methylethyl acetate	LC50 Inhalation Vapour	Rat	30 mg/l	4 hours
	LD50 Dermal	Rabbit	>5 g/kg	-
	LD50 Oral	Rat	6190 mg/kg	-
xylene	LD50 Dermal	Rabbit	1.7 g/kg	-
	LD50 Oral	Rat	4.3 g/kg	-
ethylbenzene	LC50 Inhalation Vapour	Rat	17.8 mg/l	4 hours
	LD50 Dermal	Rabbit	17.8 g/kg	-
	LD50 Oral	Rat	3.5 g/kg	-
m-tolylidene diisocyanate	LC50 Inhalation Vapour	Rat	0.48 mg/l	1 hours
	LD50 Dermal	Rabbit	>9440 mg/kg	-
	LD50 Oral	Rat	5.8 g/kg	-

Conclusion/Summary : There are no data available on the mixture itself.

Acute toxicity estimates

Product/ingredient name	Oral (mg/ kg)	Dermal (mg/kg)	Inhalation (gases) (ppm)	Inhalation (vapours) (mg/l)	Inhalation (dusts and mists) (mg/l)
SIGMALINE 859 REP HARDENER	N/A	19896.4	N/A	51.2	4.3
Isocyanic acid, polymethylenepolyphenylene ester	49000	N/A	N/A	N/A	1.5
4,4'-methylenediphenyl diisocyanate	9200	N/A	N/A	N/A	1.5
2-methoxy-1-methylethyl acetate	6190	N/A	N/A	30	N/A
xylene	4300	1700	N/A	11	N/A
o-(p-isocyanatobenzyl)phenyl isocyanate	N/A	N/A	N/A	N/A	1.5
ethylbenzene	3500	17800	N/A	17.8	N/A
2,2'-methylenediphenyl diisocyanate	N/A	N/A	N/A	N/A	1.5
m-tolylidene diisocyanate	5800	N/A	N/A	0.24	N/A

Irritation/Corrosion

Product/ingredient name	Result	Species	Score	Exposure	Observation
4,4'-methylenediphenyl diisocyanate	Skin - Irritant	Rabbit	-	-	-
xylene	Skin - Moderate irritant	Rabbit	-	24 hours 500 mg	-
Conclusion/Summary	: Not available.	·			· · · · · · · · · · · · · · · · · · ·
Skin	: There are no data available or	n the mixture its	self.		

Eves	: There are no data available on the mixture itself.
Lyco	

: There are no data available on the mixture itself.

Respiratory Sensitisation

Code : 00168694 SIGMALINE 859 REP HARDENER Date of issue/Date of revision

: 7 November 2022

SECTION 11: Toxicological information

Product/ingredient name	Route of exposure	Species		Result	
4,4'-methylenediphenyl diisocyanate	Respiratory	Guinea pig		Sensitising	
,	skin	Mouse		Sensitising	
Conclusion/Summary					
Skin	: There are no dat	ta available o	on the mixture itself		
Respiratory	: There are no dat	ta available o	on the mixture itself		
Mutagenicity					
Conclusion/Summary	: There are no data available on the mixture itself.				
Carcinogenicity					
Product/ingredient name	Resul	t	Species	Dose	Exposure
4,4'-methylenediphenyl diisocyanate	Positive - Inhalation - TC		Rat	0 to 6 mg/m ³	2 years; 5 days per week
Conclusion/Summary	: There are no data available on the mixture itself.				
Reproductive toxicity					
Conclusion/Summary	: There are no data available on the mixture itself.				
Teratogenicity					
Conclusion/Summary					

There are no data available on the mixture itself.

Specific target organ toxicity (single exposure)

Product/ingredient name	Category	Route of exposure	Target organs
Isocyanic acid, polymethylenepolyphenylene ester	Category 3	-	Respiratory tract irritation
4,4'-methylenediphenyl diisocyanate	Category 3	-	Respiratory tract irritation
2-methoxy-1-methylethyl acetate	Category 3	-	Narcotic effects
xylene	Category 3	-	Respiratory tract irritation
o-(p-isocyanatobenzyl)phenyl isocyanate	Category 3	-	Respiratory tract irritation
2,2'-methylenediphenyl diisocyanate	Category 3	-	Respiratory tract irritation
m-tolylidene diisocyanate	Category 3	-	Respiratory tract irritation

Specific target organ toxicity (repeated exposure)

Product/ingredient name	Category	Route of exposure	Target organs
Isocyanic acid, polymethylenepolyphenylene ester 4,4'-methylenediphenyl diisocyanate o-(p-isocyanatobenzyl)phenyl isocyanate ethylbenzene 2,2'-methylenediphenyl diisocyanate	Category 2 Category 2 Category 2 Category 2 Category 2	inhalation - - - -	- - hearing organs -

Aspiration hazard

Product/ingredient name	Result
xylene	ASPIRATION HAZARD - Category 1
ethylbenzene	ASPIRATION HAZARD - Category 1

Information on likely routes : Not available. of exposure

Potential acute health effects

English (GB)

Code : 00168	3694	Date of issue/Date of revision	: 7 November 2022
SIGMALINE 859 REP	PHARDENER		
SECTION 11: T	oxicological inform	nation	
Eve contact		ove irritation	

Eye contact	: Causes senous eye initation.
Inhalation	 Harmful if inhaled. May cause respiratory irritation. May cause allergy or asthma symptoms or breathing difficulties if inhaled.
Skin contact	: Causes skin irritation. Defatting to the skin. May cause an allergic skin reaction.
Ingestion	: No known significant effects or critical hazards.

Symptoms related to the physical, chemical and toxicological characteristics

Eye contact	: Adverse symptoms may include the following: pain or irritation watering redness
Inhalation	: Adverse symptoms may include the following: respiratory tract irritation coughing wheezing and breathing difficulties asthma
Skin contact	: Adverse symptoms may include the following: irritation redness dryness cracking
Ingestion	: No specific data.

Delayed and immediate effects as well as chronic effects from short and long-term exposure Short term exposure **Potential immediate** : Not available. effects **Potential delayed effects** : Not available. Long term exposure **Potential immediate** : Not available. effects **Potential delayed effects** : Not available. Potential chronic health effects Not available. **Conclusion/Summary** : Not available. : May cause damage to organs through prolonged or repeated exposure. Prolonged General or repeated contact can defat the skin and lead to irritation, cracking and/or dermatitis. Once sensitized, a severe allergic reaction may occur when subsequently exposed to very low levels. Carcinogenicity : Suspected of causing cancer. Risk of cancer depends on duration and level of exposure. **Mutagenicity** : No known significant effects or critical hazards. **Reproductive toxicity** : No known significant effects or critical hazards. **Other information** : Not available.

Code	: 00168694	Date of issue/Date of revision	: 7 Nove
SIGMALINE	859 REP HARDENER		

7 November 2022

SECTION 12: Ecological information

12.1 Toxicity

Product/ingredient name	Result	Species	Exposure
2-methoxy-1-methylethyl acetate	Acute LC50 134 mg/l Fresh water	Fish - Trout - Oncorhynchus mykiss	96 hours
ethylbenzene	Acute EC50 1.8 mg/l Fresh water Chronic NOEC 1 mg/l Fresh water	Daphnia Daphnia - Ceriodaphnia dubia	48 hours -
m-tolylidene diisocyanate	Acute EC50 12.5 mg/l	Daphnia	48 hours

Conclusion/Summary : Not available.

12.2 Persistence and degradability

Product/ingredient name	Test	Result	Dose	Inoculum
2-methoxy-1-methylethyl acetate	-	83 % - Readily - 28 days	-	-
ethylbenzene	-	79 % - Readily - 10 days	-	-
Conclusion/Summary	: Not available.			

Aquatic half-life	Photolysis	Biodegradability
-	-	Readily
-	-	Readily Readily Not readily
	· - -	

12.3 Bioaccumulative potential

Product/ingredient name	LogPow	BCF	Potential
4,4'-methylenediphenyl diisocyanate	4.51	-	high
2-methoxy-1-methylethyl acetate	1.2	-	low
xylene	3.12	7.4 to 18.5	low
o-(p-isocyanatobenzyl) phenyl isocyanate	4.51	-	high
ethylbenzene	3.6	79.43	low
2,2 [′] -methylenediphenyl diisocyanate	5.22	-	high
m-tolylidene diisocyanate	3.43	-	low

12.4 Mobility in soil

Soil/water partition coefficient (Koc)	: Not available.
Mobility	: Not available.

12.5 Results of PBT and vPvB assessment

This mixture does not contain any substances that are assessed to be a PBT or a vPvB.

12.6 Other adverse effects : No known significant effects or critical hazards.

Code	: 00168694	Date of issue/Date of revision	: 7 November 2022
SIGMALINE 8	359 REP HARDENER		

SECTION 13: Disposal considerations

The information in this section contains generic advice and guidance. The list of Identified Uses in Section 1 should be consulted for any available use-specific information provided in the Exposure Scenario(s).

13.1 Waste treatment meth	nods
Product	
Methods of disposal	: The generation of waste should be avoided or minimised wherever possible. Disposal of this product, solutions and any by-products should at all times comply with the requirements of environmental protection and waste disposal legislation and any regional local authority requirements. Dispose of surplus and non- recyclable products via a licensed waste disposal contractor. Waste should not be disposed of untreated to the sewer unless fully compliant with the requirements of all authorities with jurisdiction.
Hazardous waste	: Yes.

Waste catalogue

Waste code	Waste designation
08 01 11*	waste paint and varnish containing organic solvents or other hazardous substances

Packaging

Methods of disposal

: The generation of waste should be avoided or minimised wherever possible. Waste packaging should be recycled. Incineration or landfill should only be considered when recycling is not feasible.

Type of packaging	Waste catalogue		
Container	15 01 06	mixed packaging	
Special precautions	taken wher Empty cont residues m container. thoroughly	al and its container must be disposed of in a safe way. Care should be handling emptied containers that have not been cleaned or rinsed out. ainers or liners may retain some product residues. Vapour from product ay create a highly flammable or explosive atmosphere inside the Do not cut, weld or grind used containers unless they have been cleaned internally. Avoid dispersal of spilt material and runoff and contact with vays, drains and sewers.	

SECTION 14: Transport information

	ADR/RID	ADN	IMDG	ΙΑΤΑ
14.1 UN number	UN1263	UN1263	UN1263	UN1263
14.2 UN proper shipping name	PAINT RELATED MATERIAL	PAINT RELATED MATERIAL	PAINT RELATED MATERIAL	PAINT RELATED MATERIAL
14.3 Transport hazard class(es)	3	3	3	3
14.4 Packing group	Ш	Ш	Ш	111
14.5 Environmental hazards	No.	No.	No.	No.
Marine pollutant substances	Not applicable.	Not applicable.	Not applicable.	Not applicable.
Additional information				
ADR/RID : This class 3 viscous liquid is not subject to regulation in packagings up to 450 L according to 2.2.3.1.5.1.				
Tunnel code :	(D/E)			

ADN : This class 3 viscous liquid is not subject to regulation in packagings up to 450 L according to 2.2.3.1.5.1.

IMDG

<mark>Code</mark> SIGMALINE	: 00168694 E 859 REP HARDENER	Date of issue/Date of revision	: 7 November 2022	
SECTION 14: Transport information				
ΙΑΤΑ	: None identified.			

14.6 Special precautions for user : Transport within user's premises: always transport in closed containers that are upright and secure. Ensure that persons transporting the product know what to do in the event of an accident or spillage.

14.7 Transport in bulk: Not available.according to IMOinstruments

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture UK (GB) /REACH

Annex XIV - List of substances subject to authorisation

Annex XIV

None of the components are listed.

Substances of very high concern

None of the components are listed.

Ozone depleting substances

Not listed.

 Annex XVII - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles
 : As from August 24 2023 adequate training is required before industrial or professional use.

Seveso Directive

This product is controlled under the Seveso Directive.

Danger criteria

Category

P5c

SECTION 16: Other information

Indicates information that has changed from previously issued version.

EUH statement = GB CLP-specific Hazard statement N/A = Not available PBT = Persistent, Bioaccumulative and Toxic PNEC = Predicted No Effect Concentration RRN = REACH Registration Number SGG = Segregation Group vPvB = Very Persistent and Very Bioaccumulative	2019
Procedure used to derive the classification	

Procedure used to derive the classification

Code	: 00168694	Date of issue/Date of revision	: 7 November 2022

SIGMALINE 859 REP HARDENER

SECTION 16: Other information

Classification	Justification
Flam. Liq. 3, H226	On basis of test data
Acute Tox. 4, H332	Calculation method
Skin Irrit. 2, H315	Calculation method
Eye Irrit. 2, H319	Calculation method
Resp. Sens. 1, H334	Calculation method
Skin Sens. 1, H317	Calculation method
Carc. 2, H351	Calculation method
STOT SE 3, H335	Calculation method
STOT RE 2, H373	Calculation method

Full text of abbreviated H statements

H225	Highly flammable liquid and vapour.
H226	Flammable liquid and vapour.
H304	May be fatal if swallowed and enters airways.
H312	Harmful in contact with skin.
H315	Causes skin irritation.
H317	May cause an allergic skin reaction.
H319	Causes serious eye irritation.
H330	Fatal if inhaled.
H332	Harmful if inhaled.
H334	May cause allergy or asthma symptoms or breathing difficulties if inhaled.
H335	May cause respiratory irritation.
H336	May cause drowsiness or dizziness.
H351	Suspected of causing cancer.
H373	May cause damage to organs through prolonged or repeated exposure.
H412	Harmful to aquatic life with long lasting effects.

Full text of classifications

Acute Tox. 1	ACUTE TOXICITY - Category 1
Acute Tox. 4	ACUTE TOXICITY - Category 4
Aquatic Chronic 3	LONG-TERM (CHRONIC) AQUATIC HAZARD - Category 3
Asp. Tox. 1	ASPIRATION HAZARD - Category 1
Carc. 2	CARCINOGENICITY - Category 2
Eye Irrit. 2	SERIOUS EYE DAMAGE/EYE IRRITATION - Category 2
Flam. Liq. 2	FLAMMABLE LIQUIDS - Category 2
Flam. Liq. 3	FLAMMABLE LIQUIDS - Category 3
Resp. Sens. 1	RESPIRATORY SENSITISATION - Category 1
Skin Irrit. 2	SKIN CORROSION/IRRITATION - Category 2
Skin Sens. 1	SKIN SENSITISATION - Category 1
STOT RE 2	SPECIFIC TARGET ORGAN TOXICITY - REPEATED EXPOSURE - Category 2
STOT SE 3	SPECIFIC TARGET ORGAN TOXICITY - SINGLE EXPOSURE - Category 3

<u>History</u>

Date of issue/ Date of revision	11/7/2022
Date of previous issue	No previous validation
Prepared by	EHS
Version	: 1

<u>Disclaimer</u>

The information contained in this data sheet is based on present scientific and technical knowledge. The purpose of this information is to draw attention to the health and safety aspects concerning the products supplied by us, and to recommend precautionary measures for the storage and handling of the products. No warranty or guarantee is given in respect of the properties of the products. No liability can be accepted for any failure to observe the precautionary measures described in this data sheet or for any misuse of the products.